Clinical experiments "encouraging" can lead to the treatment of 'blindness headaches'

The second phase of clinical experiments associated with a new treatment for ‘blindness headache’ has achieved encouraging results that are “a step forward” on the way to achieving medicines licensed to deal with this disease that leaves patients with life problems. The results, published by researchers at the English University of Birmingham, indicated that the drug known as ‘Presandin’ targets a group of neuro transfer fabrics by linking it and preventing it from working and causing the disease. The ‘blindness of blindness’ is caused by high blood pressure in the skull without a clear reason, as the disease begins with a daily or almost daily headache, and affects at the beginning of the head at the beginning, and changes the vision, and two boys in the head, and this can lead to a chronic headache and the loss of vision permanently. The experiment, published in the “Brain” journal, found that the pressure in the brain decreased from the seven patients who received regular treatment during the short measurements that varied between 2.5 hours and 24 hours, and the long to 12 weeks. The disease usually affects women between the ages of 25 and 36, and weight gain is one of the most important risk factors it causes. The second phase of the experiment led to the reduced brain pressure in the participants immediately, and more than 12 weeks, in addition to reducing headaches by about 8 days during the period as a whole. All women were able to continue with some harmful effects with the treatment. This was seen by infection with high blood pressure without clear reasons, in the past, so rare, but it has eventually increased significantly in accordance with the global increase in obesity, as cases have increased by 350% over the past decade. The new drug is linked to a future called “GLP-1”, and scientists believe that this is the main cause of this disease. Scientists need more experiments before such treatment is available in the markets, while the results of this experiment are encouraged to make a difference for those in the cure in the clinical experiment, and the treatment may be suitable for other cases associated with high brain pressure. Also read: